ArTS Archivio della ricerca di Trieste

ZAJA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.450
AS - Asia 8.074
EU - Europa 5.652
SA - Sud America 1.338
AF - Africa 319
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 3
Totale 28.854
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.228
SG - Singapore 3.338
CN - Cina 1.418
PL - Polonia 1.246
HK - Hong Kong 1.148
BR - Brasile 1.025
SE - Svezia 897
VN - Vietnam 882
IT - Italia 763
DE - Germania 497
FR - Francia 466
KR - Corea 424
RU - Federazione Russa 375
BG - Bulgaria 274
IE - Irlanda 273
IN - India 226
GB - Regno Unito 203
FI - Finlandia 200
MA - Marocco 137
CA - Canada 116
NL - Olanda 114
AR - Argentina 109
BD - Bangladesh 89
TR - Turchia 77
JP - Giappone 72
UA - Ucraina 69
ES - Italia 67
EC - Ecuador 63
MX - Messico 62
ID - Indonesia 56
ZA - Sudafrica 53
AT - Austria 47
IQ - Iraq 44
PK - Pakistan 40
CH - Svizzera 30
CO - Colombia 28
CZ - Repubblica Ceca 28
SN - Senegal 27
IL - Israele 26
PY - Paraguay 26
SA - Arabia Saudita 25
UZ - Uzbekistan 25
VE - Venezuela 25
BE - Belgio 22
CL - Cile 22
EG - Egitto 21
PH - Filippine 20
JO - Giordania 19
AU - Australia 17
AE - Emirati Arabi Uniti 15
DZ - Algeria 15
TN - Tunisia 15
BO - Bolivia 14
KE - Kenya 14
NP - Nepal 13
LT - Lituania 12
PE - Perù 12
RO - Romania 12
UY - Uruguay 12
MY - Malesia 11
IR - Iran 10
TW - Taiwan 10
DO - Repubblica Dominicana 9
TH - Thailandia 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
TT - Trinidad e Tobago 8
AO - Angola 7
ET - Etiopia 7
HU - Ungheria 7
JM - Giamaica 7
KG - Kirghizistan 7
LK - Sri Lanka 7
OM - Oman 7
CI - Costa d'Avorio 6
CR - Costa Rica 6
HR - Croazia 6
LB - Libano 5
LV - Lettonia 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
BA - Bosnia-Erzegovina 4
BB - Barbados 4
DK - Danimarca 4
GR - Grecia 4
LA - Repubblica Popolare Democratica del Laos 4
MN - Mongolia 4
NO - Norvegia 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BH - Bahrain 3
GA - Gabon 3
GE - Georgia 3
KW - Kuwait 3
PT - Portogallo 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
EE - Estonia 2
GY - Guiana 2
Totale 28.814
Salva come PNG Salva come JPEG
Città #
Singapore 2.241
Ashburn 1.640
Fairfield 1.597
Hong Kong 1.137
Warsaw 952
San Jose 848
Woodbridge 769
Seattle 666
Houston 662
Wilmington 616
Chandler 596
Cambridge 517
Princeton 478
Boardman 425
Seoul 416
Beijing 407
Santa Clara 314
Ho Chi Minh City 296
Chicago 292
Ann Arbor 290
Sofia 270
Dublin 268
Lauterbourg 264
Zgierz 262
Columbus 252
Jacksonville 245
Munich 240
Hefei 229
Trieste 189
Hanoi 173
The Dalles 168
Moscow 157
Helsinki 149
San Diego 127
Dallas 125
Los Angeles 124
Milan 118
Casablanca 113
Council Bluffs 96
São Paulo 85
Frankfurt am Main 81
New York 65
London 55
Düsseldorf 42
Montreal 41
Buffalo 40
Mumbai 39
Orem 39
Da Nang 38
Dong Ket 36
Norwalk 35
Tokyo 33
Chennai 29
Haiphong 29
Johannesburg 29
Nuremberg 29
Phoenix 29
Guangzhou 27
Nanjing 27
Tianjin 27
Vienna 27
Dakar 26
Stockholm 26
Boston 25
Brooklyn 25
Redondo Beach 25
Redwood City 25
Shanghai 25
Miano 24
Rome 24
Toronto 24
Belo Horizonte 23
Rio de Janeiro 23
Campinas 22
San Francisco 22
Washington 22
Atlanta 21
Bremen 21
Quito 21
Tashkent 21
Bern 19
Curitiba 19
Jinan 19
Brasília 18
Brno 18
Poplar 18
Turku 18
Baghdad 17
Brussels 17
Dearborn 17
Dhaka 17
Hải Dương 17
Lappeenranta 17
Manchester 17
Amman 16
Can Tho 16
Denver 16
Guayaquil 16
Biên Hòa 15
Jeddah 15
Totale 20.397
Salva come PNG Salva come JPEG
Nome #
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival 470
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 394
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 372
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 341
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations 322
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. 239
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components 239
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 220
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. 220
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 205
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT) 200
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 200
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 187
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 185
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 177
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 176
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 175
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 174
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? 172
Low-dose rituximab in adult patients with primary immune thrombocytopenia 172
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 172
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice 170
Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies 169
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 168
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 163
TP53 mutations with low variant allele frequency predict short survival in Chronic Lymphocytic Leukemia 162
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 161
Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019? 161
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 159
Bendamustine salvage therapy for T cell neoplasms 157
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion 157
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis 157
Rituximab for the treatment of type II mixed cryoglobulinemia 156
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia 156
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 155
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 154
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 154
A case report of isolated cardiac light chain amyloidosis without clinically overt heart failure: an under-recognized presentation 153
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 153
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 152
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 151
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 149
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 149
B-cell depletion with rituximab as treatment for autoimmune thrombocytopenia 148
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response 148
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 148
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 148
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 146
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab 145
Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors 145
Management of immune thrombocytopenia in elderly patients 144
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients 144
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 141
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 140
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters 138
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 138
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 137
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 136
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 135
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 135
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 134
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 132
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 132
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 131
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 130
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study 130
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 129
Updated international consensus report on the investigation and management of primary immune thrombocytopenia 129
Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network 128
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 127
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL 127
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 126
Rituximab in a case of cold agglutinin disease 125
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 125
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab 124
CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies? 124
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation 124
Preventive versus curative photobiomodulation for oral mucositis in patients with multiple myeloma undergoing hematopoietic stem cell transplantation: which approach is more effective? 124
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi 123
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 122
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma 122
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 122
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia 121
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 121
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 120
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 120
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 120
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 119
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 118
Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance 117
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-κ B pathways 117
High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome 116
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 115
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 114
Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia 114
Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study 113
Mycophenolate Mofetil for Immune Thrombocytopenia. Reply 113
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice 112
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 112
Treatment of refractory chronic GVHD with rituximab: a GITMO study 110
Totale 15.776
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.499
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021948 0 0 0 0 0 0 0 0 0 333 164 451
2021/20222.370 57 269 64 240 18 77 169 109 312 234 108 713
2022/20232.377 304 268 241 177 246 473 10 225 270 39 89 35
2023/20241.983 87 75 142 51 83 217 335 626 46 36 129 156
2024/20255.983 48 864 946 412 385 461 390 322 536 560 429 630
2025/20269.823 934 441 651 1.105 905 874 1.607 431 1.260 1.615 0 0
Totale 29.670